Golden
Codagenix

Codagenix

Codagenix is a biotechnology company developing live attenuated vaccines.

Codagenix is a privately held, biotechnology company based in Stony Brook, New York. The company focuses on constructing live-attenuated viral vaccines against multiple targets using the company's proprietary technology platform, SAVE. Standing for Synthetic Attenuated Virus Engineering, the platform relies on synthetic biology and the rational 're-design' of a target virus' entire genome to yield a vaccine strain. The customization process uses software-based algorithms to 're-code' the genome of a target virus. 



The company's product pipeline includes vaccines for influenza, respiratory syncytial virus (RSV), dengue, foot and mouth disease virus (FMDV), pathogenic E. Coli, and other targets.

Timeline

People

Name
Role
LinkedIn

Eckard Wimmer

Co-Founder, Senior Scientific Officer



J. Robert Coleman

Co-Founder & COO



Rishab Kaul

Employee



Steffen Mueller

Co-Founder, President, and Chief Scientific Officer



Further reading

Title
Author
Link
Type
Date

Xconomy: With $2M, Codagenix Becomes Accelerate LI's First VC-Backed Grad



Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References